

21 May 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen's Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan's pharma firms; and new Tagrisso data lift AstraZeneca.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 19 May 2023, including: US FTC takes action on [Amgen, Inc.'s Horizon Therapeutics plc](#) deal; Hassan and Jimenez share their CEO experiences; [Novartis AG](#) lays out Cosentyx plans; generally strong fiscal year for Japan's pharma firms; and new Tagrisso data lift [AstraZeneca PLC](#).

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[FTC's Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices](#)" - Scrip, 16 May, 2023.)

(Also see "[The Benefit Of Hindsight: Strategic Leadership Lessons From Pharma's Past CEOs](#)" - Scrip, 16 May, 2023.)

(Also see "[Novartis Committed To Carving Out More Indications For Cosentyx](#)" - Scrip, 12 May, 2023.)

SCRIP

CITELINE COMMERCIAL

(Also see "[Japan Results Round-Up: Astellas, Daiichi Sankyo, Chugai Solid, Shionogi Hits New Heights](#)" - Scrip, 16 May, 2023.)

(Also see "[AstraZeneca Lifted By Tagrisso Combo Lung Cancer Data](#)" - Scrip, 17 May, 2023.)

[Click here to explore this interactive content online](#) 